INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • February 14th, 2014 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made on August 29, 2007 (the “Effective Date”) by and among Cyrenaic Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors listed on Schedule I hereto (the “Investors”).
PROMISSORY NOTEPromissory Note • February 14th, 2014 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • Delaware
WHEREAS, Sonkei Pharmaceuticals, Inc., a Delaware corporation (the “Company”) has agreed to sell 1,112,500 shares of Company stock (“Restricted Stock”) to Maker, pursuant to that certain Subscription Agreement, dated as of the date hereof (the “Grant Agreement”);
PROMISSORY NOTEMinerva Neurosciences, Inc. • February 14th, 2014 • Pharmaceutical preparations • Delaware
WHEREAS, Minerva Neurosciences, Inc., a Delaware corporation (the “Company”) has agreed to sell 97,737 shares of Company stock (“Restricted Stock”) to Maker, pursuant to that certain Subscription Agreement, dated as of the date hereof (the “Grant Agreement”);
October 4, 2013 Dr. Rogerio Vivaldi Coelho Brookline, MA, 02467 US Dear Rogerio:Minerva Neurosciences, Inc. • February 14th, 2014 • Pharmaceutical preparations • Massachusetts
Further to our offer letter to you dated September 17, 2013 (the “Offer Letter”), this agreement (this “Employment Agreement”) will formalize the terms and conditions of your employment with Cyrenaic Pharmaceuticals, Inc. (the “Company”).
December 23, 2013 Joseph Reilly 12 Nelson Way Wilmington, MA 01887 Dear Joe:Minerva Neurosciences, Inc. • February 14th, 2014 • Pharmaceutical preparations • Massachusetts
Further to our offer letter to you dated December 13, 2013 (the “Offer Letter”), this agreement (this “Employment Agreement”) will formalize the terms and conditions of your employment with Minerva Neurosciences, Inc. (the “Company”).
AMENDMENT NO. 1 TO INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • February 14th, 2014 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 1 TO INVESTMENT RIGHTS AGREEMENT (this “Amendment”), dated as of December 20, 2013, is made by and among Minerva Neurosciences, Inc., a Delaware corporation, as the corporate successor to Cyrenaic Pharmaceuticals, Inc. (the “Company”), and the undersigned investors of the Company (the “Investors”).
